- News>
- Companies & Commodities
Ranbaxy receives FDA approval for generic vantin tablets
New Delhi, Aug 25: The United States Food and Drug Administration (FDA) has given its approval to Indian pharma major Ranbaxy Laboratories Ltd (RLL) to market a tablet form of anti-biotic Cefpodoxime Proxetil in the US, according to the FDA website.
New Delhi, Aug 25: The United States Food and Drug Administration (FDA) has given its approval to Indian pharma major Ranbaxy Laboratories Ltd (RLL) to market a tablet form of anti-biotic Cefpodoxime Proxetil in the US, according to the FDA website.
Originally from Pharmacia Corp, the drug is now a part of global drugmaker giant Pfizer which markets it under the brand -- Vantin.
RLL had received FDA nod to market an oral suspension form of the drug in may last year. However, litigation, initiated by Pharmacia to stop it from selling the drug, continues.
Last week, Ranbaxy had received FDA nod to market a generic version of Schering-Plough Corp's anti-allergy Claritin tablets in the 10 mg strength. Bureau Report
RLL had received FDA nod to market an oral suspension form of the drug in may last year. However, litigation, initiated by Pharmacia to stop it from selling the drug, continues.
Last week, Ranbaxy had received FDA nod to market a generic version of Schering-Plough Corp's anti-allergy Claritin tablets in the 10 mg strength. Bureau Report